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Abstract 
 
Background: The fortuitous discovery of an animal pigment bilirubin found in the plant Strelitzia nicolai has opened 
an enormous number of questions regarding bilirubin’s formation and its ultimate function in the human body. 
Materials and Methods: A methodical review of bilirubin in humans and animals was carried out, information was 
gathered using published scientific journals, books and conference proceedings. Articles based on case studies of 
elevated levels of bilirubin were analysed thoroughly.  
Results: Even though for numerous years bilirubin was assumed to be merely a desecrate product of the heme catabolic 
pathway by greatest, and a likely lethal compound at worst; statistics from the last few decades clearly shows that 
placidly high serum bilirubin levels are robustly related to have abundant beneficial effects on the human body. 
Conclusion: This study reveals new insights into the presence of the only animal pigment found in Strelitzia nicolai 
arils, the potential advantages of bilirubin found in a plant and its therapeutic value indications. This review hopes to 
resuscitate researchers’ credence regarding bilirubin as a toxic compound.   
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Introduction 
 
The catabolism of haem is the only natural progression in human beings that is colorimetric. This process would have 
been recognized by early man several thousand decades ago. After being injured directly on the skin a contusion that 
was black or purple (colours of haem) progressively changed to olive, the colour of biliverdin, and ultimately to yellow, 
the colour of bilirubin (Otterbein and Choi, 2000). Previously thought to be an “animal-only” pigment, in 2009, Florida 
International University researchers’ (Pirone, 2010), made a breakthrough discovery in finding bilirubin in the arils 
of Strelitzia nicolai Regel and Koern, commonly known as the white bird of paradise. Bilirubin is a by-product from 
the secondary degradation of haem, the primary being biliverdin. In birds, reptiles and amphibians, biliverdin is the 
principal end product of heme dilapidation. In mammals, biliverdin endures an added metabolism to form bilirubin. 
This phenomenon has always mystified scientists.  
 
Formation of Bilirubin in humans  
 
Bilirubin is the terminal product of haem metabolism. Haem  are established in haemoglobin, the major component of 
red blood cells. In humans, 250–400 mg of bilirubin are produced daily, of which more or less 20% is produced from 
non-haemoglobin sources (London et al., 1950). The conversion of haem to bilirubin is a two step procedure (Figure 1). 
First, microsomal heme oxygenase (HO), enzyme catalyses the oxidation of haem to a green tetrapyrrolic bile pigment, 
biliverdin. Subsequently biliverdin is transformed to bilirubin by biliverdin reductase (McDonagh, 2001). This reaction 
can occur in nearly every cell. An illustration is the formation of a bruise that undergoes different colours as it 
progressively mends i.e. red haem to green biliverdin to yellow bilirubin. Under standard physiological circumstances, 
the motion of haem oxygenase peaks in the spleen, where mature erythrocytes are sequestrated and annihilated. 
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Figure 1: Enzyme-catalysed degradation of heme (Ramadori et al., 2000). Haem degradation starts by haem 
oxygenase-catalysed oxidation of the a-bridge carbon of haem that is converted to CO, directed to aperture of the 
tetrapyrrole ring which releases the iron molecule. The resulting biliverdin fragment is consequently abridged to 
bilirubin by cytosolic biliverdin reductase. 
 
Metabolism of Bilirubin 
 
Red blood cells are constantly undergoing a hemolysis course. The typical life-span of a red blood cell is 120 days. 
Whilst the red blood cells collapse, the haemoglobin is degraded or broken into globin, iron, and haem. The heme is 
first changed into biliverdin, which is quickly reduced to bilirubin. This process occurs in the reticuloendothelial cells 
of the liver, spleen, and bone marrow.  
Haemoglobin, which is broken down to haeme in the spleen, is changed to form unconjugated bilirubin 
(Figure 2). This unconjugated bilirubin is insoluble in water, because of its intramolecular hydrogen bonding and 
attaches to albumin which is then sent to the liver. Inside the liver, bilirubin is conjugated through glucuronic acid  by 
the enzyme glucuronyltransferase, rendering water soluble. Most of it goes into the small intestine together with the 
bile. About 95% of the bile created is taken back up by the liver. This bile is then resecreted by the liver into the small 
intestine. The procedure is identified as the enterohepatic circulation. About half of the conjugated bilirubin in the large 
intestine is exercised by gut bacteria to produce urobilinogen. This is then additionally oxidized 
to urobilin and stercobilin. Urobilin, stercobilin and their disintegrated products give faeces its brown colour (Kuntz, 
2008). 
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Figure 2: The enterohepatic circulation system (Sedlak and Snyder, 2004). Bilirubin is delivered to the liver, largely 
attached to albumin. In the liver, bilirubin is conjugated, excreted in the bile, modified in the gastrointestinal tract and 
largely lost via the faeces. 
 
Bilirubin toxicity  
 
Toxicity resulting from unconjugated hyperbilirubinemia has been known for more than a century, since the 
landmark study of Schmorl (1903) describing autopsy findings from 120 jaundiced infants (Hansen, 2000). Schmorl 
(1903) contributed immensely to the understanding of epidemiology and pathophysiology of neonatal jaundice and 
kernicterus. 
Biliary efflux is the key route of removal of bilirubin and abate excretion will lead to toxicity of intracellular 
organelles and physiological processes. Amassing of bilirubin and bilirubin conjugates in human tissues generates 
jaundice, which is distinguished by soaring plasma bilirubin levels and deposition of yellow bilirubin tinctures in skin, 
sclerae, mucous membranes, and other less noticeable tissues (Lathe, 1972). Kernicterus is a form of brain damage 
caused by excessive jaundice. 
The Gilbert syndrome is a harmless hereditary variation connected to unceasingly elevated plasma levels of 
unconjugated bilirubin (Ritter et al., 1992). This condition is emerges when the hepatic expression of the enzyme that 
conjugates bilirubin, glucuronosyltransferase type 1A1, is reduced. A more lethal inherited disorder affecting 
the metabolism of bilirubin is called the Crigler–Najjar syndrome. This uncommon disorder is a hereditary form of 
non-haemolytic jaundice, which is caused by mutations in the UGT1A gene encoding bilirubin 
glucuronosyltransferase. These produce elevated levels of unconjugated bilirubin which frequently directs to brain 
damage in infants (Ritter et al., 1992). 
The Dubin–Johnson disease is an autosomal recessive condition which brings about an addition of 
conjugated bilirubin in the serum with no increase of liver enzymes (ALT, AST). The above disorder is fabricated by 
the insufficiency of canalicular multispecific organic anion transporter (cMOAT) gene (ABCC2/MRP2). This is 
connected to a flaw in the capability of hepatocytes to secrete conjugated bilirubin into the bile (Paulusma, et al., 1997). 
Mutations in the SLCO1B1 and SLCO1B3 genes cause the Rotor syndrome (non-icteric jaundice). 
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The SLCO1B1 and SLCO1B3 genes code for creating proteins, called organic anion transporting polypeptide 1B1 
(OATP1B1) and organic anion transporting polypeptide 1B3 (OATP1B3). The above proteins are established in the 
liver cells; these proteins convey bilirubin, starting from the blood heme to the liver. The SLCO1B1 and SLCO1B3 gene 
alterations that produces the Rotor syndrome lead to strangely small, nonfunctional OATP1B1 and OATP1B3 proteins 
or a nonexistence of these proteins. Lacking the occupation of these transfer protein, bilirubin is reducibly taken up by 
the liver and eliminated from the body (Strassburg, 2010).  
 
Potential beneficial effects of bilirubin 
 
For many years, unconjugated bilirubin (UCB) was considered a useless waste product of haeme catabolism, 
with no physiological function, but with potential toxicity. If this was a reality, then, why would the energy intense 
conversion of biliverdin to the water insoluble ‘hazardous’ bilirubin, which requires additional resources for shipping 
and secretion, occur? The breakthrough of finding the antioxidant and other properties of bilirubin has proposed that 
this conversion of biliverdin to bilirubin may actually be in reality, a progress in evolution (McDonagh, 2001). On the 
other hand Cornelius (1986), established that the enzyme biliverdin reductase existed even in Cyanobacteria, far prior to 
the existence of Eukaryotes on earth. Qin (2007), proposed that the inactivation of digestive proteases is the 
evolutionary dynamic strength for bilirubin preponderance. The quantity of digestive proteases secreted by the pancreas 
largely relies on the quantity of protein that is consumed. The quantity of digestive proteases secreted by the pancreas 
largely relies on the quantity of protein that is consumed. This presents a justification for the examination so as to 
bilirubin’s principal genera be likely chosen carnivores or omnivores, whilst biliverdin‐chief class tend to be herbivores 
(Howard and Yudkin, 1963). 
Near the beginning of 1950, bilirubin was alleged to guard against the oxidation of lipids for instance, linoleic 
acid and vitamin A (Bernhard et al., 1954). Interestingly, evidence obtained in the last decade revealed a beneficial role 
of the molecule. Undeniably, physiological or modestly elevated serum levels of UCB have been shown to have a 
protective effect in several disorders, paradoxically even including neurodegenerative diseases. Protective effects of 
UCB rely on its antioxidant properties (Cuadrado and Rojo, 2008). Not only does bilirubin protect against oxidation, 
but it has also been reported to be beneficial against amylotrophic lateral sclerosis (Iłżecka and Stelmasiak, 2003), 
atopic dermatitis (Tsukahara et al., 1976), cancer (Temme et al., 2001) and Coronary artery disease (Hopkins et al., 
1996). In diabetes mellitus, Han et al., (2010) discovered that an elevated intensity of serum bilirubin is related with a 
poorer hazard of the ailment. 
 
Bilirubin as an antioxidant and cytoprotectant 
 
Oxidative stress is damaging to life progression and is mainly accountable for maturation and age-related 
diseases. Oxidative stress is fundamentally a disproportion among the manufacturing of free radicals and the capability 
of the cells to counteract their damaging effects. For that reason, generally, the body is capable of producing a range of 
natural defence mechanisms in opposition to oxidative stress. 
Thomas et al., (2008), found that the bilirubin pathway was a physiological cytoprotectant. Bilirubin principally 
defends against lipid peroxidation. This antioxidant effect impacts cell continued existence, As cell loss is additionally 
clearly amplified following reduction of bilirubin. Once bilirubin performs as an antioxidant, it is oxidized to 
biliverdin, biliverdin is then instantly reduced by biliverdin reductase to bilirubin. 
Llesuy and Tomaro (1994), found that an increase in bilirubin production may perhaps be a reaction to early 
oxidative stress. They discovered that administering CO (II) to rats lead to oxidative stress, which precedes haem 
oxygenase stimulation. The introduction of this enzyme might be a method, during the amplification of bilirubin levels, 
to reduce the harm ignited by oxidative stress. During the infant period, most of the natural antioxidant level is fairly 
low compared to bilirubin. Bilirubin, which is deadly to neuronal cells at elevated levels, has been reported to have 
cytoprotective activity at lower concentrations (Breimer et al., 1995). Neonatal jaundice might also have a defensive 
outcome for the newborn moving for the first moment in time into an unhygienic environment. An investigation based 
on fit individuals assembled by low, in-between and elevated serum bilirubin intensity disclosed that high bilirubin 
levels guard against coronary flow reserve impairment, coronary microvascular dysfunction, and probably coronary 
atherosclerosis as well (Gullu et al., 2005). Biliverdin reductase is an evolutionarily preserved enzyme, renovating 
biliverdin to bilirubin, the potent physiological antioxidant. Bilirubin defends cells in opposition to high levels of 
hydrogen peroxide (H2O2), which oxidises bilirubin into biliverdin, which is then recycled flipside into bilirubin by 
biliverdin reductase (Baranano et al., 2002). 
 
Bilirubin as an anti-cancer agent 
 
Cancer is a term used for diseases in which atypical cells multiply without control and are able to invade other 
tissues. Cancer is a conglomerate of diseases. There are numerous types of cancers that are named according to the 
organ they affect. 
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Zucker et al., (2004) researched a huge amount of people in the United States and with this they found that the 
probability proportion for colorectal cancer is condensed to 0.295 in men and 0.186 in women per 1 mg/dL increase in 
serum bilirubin intensity. Another study in Belgium by Temme et al., (2001) confirmed that there is a contrary 
connection among serum bilirubin concentration and cancer mortality.  
The American Association for Cancer Research (2013) found that a 7.02 occurrence rate of lung cancer per 
10,000 person-years for men with bilirubin concentrations of 0.68 mg/dL or a smaller amount compared with an 
prevalence rate of 3.73 amongst men whose bilirubin concentrations were 1.12 mg/dL or higher. This interprets into a 
51 % amplification in the danger for developing lung cancer for patients with reduced bilirubin. Additionally, it was 
discovered that a lung cancer-specific mortality rate of 4.84 for men with the least amount of bilirubin compared with a 
mortality rate of 2.46 for men with the highest bilirubin concentration - a 59 % increase in lung cancer-specific death 
amongst persons with the lowest bilirubin concentration. 
 
Bilirubin as a protectant in diabetes 
 
Diabetes mellitus, the trademark of which consists of higher plasma glucose, is constantly coupled with 
amplified oxidative stress, as well as improved development of complex glycation end products. Overproduction of 
oxidizing particles causes the progressive loss of pancreatic β-cells, reducing insulin levels (Yamagishi et al., 2011).  
Numerous studies have deduced that elevated bilirubin levels are contrariwise linked to the incidence of type 2 
diabetes. Korean scientists reported considerable resistance of hyperbilirubinemic Gunn rats to initiated diabetes 
following intraperitoneal contact to Streptozotocin, compared to their normobilirubinemic littermates (Fu et al., 2010). 
Cheriyath et al., (2010) confirmed that bilirubin might contribute a vital responsibility in glycemic 
management. Improved expression of haeme oxygenase-1, the enzyme responsible for the alteration of hemoglobin to 
bilirubin, is related with better insulin sensitivity and glucose metabolism. Additionally, serum bilirubin is contrariwise 
connected to insulin resistance since it amplifies the expression of glucose transporter-1 and the speed of glucose 
uptake. 
 
Bilirubin as a protectant in cardiovascular disease 
 
Cardiovascular diseases comprise hypertension, atherosclerosis, coronary artery illness and stroke. These are 
the leading causes of deaths in the world. Schwertner et al., (1994) established that a 50% reduction in total bilirubin 
was related to a 47% increment in the more rigorous coronary artery diseases.  
Gilbert’s syndrome is largely one of the frequent inherited genetic ailments. It is caused by an impaired 
glucuronyl transferase action leading from gentle to modest increase of serum bilirubin.  Vitek et al., (2002) reported 
that the occurrence of ischemic heart condition in Gilbert’s syndrome was established to be only 2%, in contrast with 
12%, in control individuals.  
Hopkins et al., (1996) established and completed a preceding study, that indicates, an increase in serum 
bilirubin level contained by the standard range is linked to a noteworthy and obvious decrease in coronary artery 
disease risk. Hopkins and Co-worker (1996) observed a 60% to 90% decrease in danger once serum bilirubin was in the 
higher two control quintiles compared with the lowest quintile for both men and women. 
 
Bilirubin as a protector against neurological diseases 
 
Takahashi et al., (2000) proposed that bilirubin is a powerful antioxidant in opposition to the cellular injure 
extracted by reactive oxygen species and contributes to the overall antioxidant network of the brain. Bilirubin has been 
established to be a powerful antioxidant in the brain, acting to forage peroxyl radicals as efficiently as α-tocopherol or 
vitamin E. 
Iwasaki et al., (2005) found that a decreased concentration of serum bilirubin is correlated to an improved 
danger of neurodegenerative diseases. In addition, a low concentration of serum bilirubin is related to an increased risk 
of amyotrophic lateral sclerosis and psychological disorders, such as winter depression and schizophrenia. 
 
The breakthrough of the only animal pigment (bilirubin) found in a plant 
 
Strelitziaceae is a tropical monocotyledon family generating colourful bracteate inflorescences with woody 
capsular fruits that contain vibrantly colored arillate seeds. Pirone, (2010) discovered in the arils of Strelitzia nicolai 
(white bird of paradise) and Strelitzia reginae (the bird of paradise), the presence of bilirubin. The seeds contain an 
inner and outer integument, micropylar zone and an appendage in the form of dense tufts of a bright orange coloured 
aril (Van de Venter, 1986). Bilirubin was present in these arils as the primary pigment, and thus functions to produce 
vivid colours to attract animals. 
Not like general plant pigments that decompose once the cell dies, aril pigments in the family endure for 
decades. Pirone, (2010) isolated the orange pigment from the arils of Strelitzia nicolai, and performed HPLC-ESMS, 
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UV-visible, H NMR and C NMR investigation to conclude its chemical structure. The chemical properties of the 
compounds were atypical, and did not equal those of known colour classes (carotenoids, flavonoids, betalains, and the 
chlorophylls). The results revealed that the pigment was bilirubin-IX, an orange-yellow tetrapyrrole until that time 
known only in mammals and some other vertebrates.  
The incidence of bilirubin discovery was not limited to S. nicolai. Two other species in the Strelitziaceae, 
Phenakospermum guyanense (A.Rich.) and S. reginae, contain aril pigments which co-eluted with genuine bilirubin in 
HPLC and had similar UV-visible spectra (Pirone, 2010). In the arils of the Strelitzia species, bilirubin was present as 
the principal pigment, and thus functioned to create colour. Previously, no tetrapyrroles were known to generate display 
colour in plants (Pirone, 2010). Bilirubin is therefore the initial creation of a further biosynthetic course, the 
tetrapyrrole pathway, to produce eye-catching colour in a plant reproductive constitution.  
Tetrapyrroles are organic particles that had the utmost impact over the progression of existence for more than 
4 billion years. These molecules play imperative roles in a variety of natural processes, including photosynthesis and 
respiration. Higher plants hold four classes of tetrapyrroles, namely, chlorophyll, haeme, siroheme, and 
phytochromobilin. Every one of the tetrapyrroles is derived from an ordinary biosynthetic pathway (McDonagh, 2001). 
The chief location of tetrapyrrole biosynthesis in plants transpires in plastids. Tetrapyrrole biosynthesis is dominantly 
regulated by acclimation to environmental conditions.  
 
 Pathway of tetrapyrrole biosynthesis  
 
The initial phase in the tetrapyrrole biosynthesis is the production of 5-aminolaevulinic acid ALA via two 
probable routes: (1) condensation of succinyl CoA and glycine (C4 pathway) using ALA synthase or (2) 
decarboxylation of glutamate (C5 pathway) via three diverse enzymes, glutamyl-tRNA synthetase to charge a tRNA 
with glutamate, glutamyl-tRNA reductase to decrease glutamyl-tRNA to glutamate-1-semialdehyde (GSA), and GSA 
aminotransferase to catalyse a transamination response to manufacture ALA (Grimm, 2003). 
The next period is to change ALA to uroporphyrinogen III. This is attained by the achievement of three 
enzymes in a single general pathway: porphobilinogen (PBG) synthase or ALA dehydratase, to condense two ALA 
fragments to produce porphobilinogen; hydroxymethylbilane synthetase, to polymerise four PBG molecules into 
preuroporphyrinogen (tetrapyrrole structure); and uroporphyrinogen III synthetase to connect two pyrrole components 
as one to yield uroporphyrinogen III (Grimm, 2003). To manufacture haem and chlorophyll, uroporphyrinogen III 
requires to be decarboxylated into coproporphyrinogen III by the act of uroporphyrinogen III decarboxylase.  
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Figure 3: Biochemical pathway of plant tetrapyrrole biosynthesis. The global precursor of all tetrapyrroles, 5-
aminolevulinic acid (ALA), is produced from glutamate. ALA is additionally processed to protoporphyrin IX before 
the approach branches into haem and chlorophyll biosynthesis (Czarnecki and Grimm, 2012). 
 
Differences and similarities of the tetrapyrrole metabolic synthesis in animals and plants 
 
The enzymatic steps are the most important differences in the pathways. Another major difference is the two 
routes of ALA synthesis, which developed independently during evolution (Tanaka and Tanaka, 2007). These two 
paths differ in the commencing metabolites. The earliest path is found in all bacteria and plants. It starts with glutamate 
and three enzymes needed to form ALA. In animals and yeasts, a succinyl-CoA-glycin entry was elucidated with one 
enzyme to form ALA (Mochizuki, 2010). 
The configuration of haem in all organisms is attained by the chronological act of eight discernible enzymes. 
The plant tetrapyrrolic pathway additionally includes several bicurations for synthesis of different products 
(Tanaka and Tanaka, 2011). 
A major distinction of plant and animal tetrapyrrolic biosynthesis pathway is the different subcellular 
localization of the pathway. The animal metabolic chain is spatially separated within the cell (Grimm, 2003). Four 
enzymes are located in the cytoplasm and another four are present in the mitochondria. In plant, the whole metabolic 
pathway for chlorophyll is located in the chloroplasts. Here the synthesis takes place in plastids and in the mitochondria 
(Jensen et al, 1999). 
 
Can bilirubin’s newfound status be harnessed therapeutically? 
 
Despite a century of research, several clinical areas of bilirubin remain poorly understood, controversial, or 
unrecognized. The breakthrough in finding profuse amounts in the orange mop like turfed arils of the seeds of the 
Strelitzia spp and Phenakospermum guyanense has opened up new opportunity for the possible insight into the 
evolutionary reason for the baffling biosynthesis in humans.  
It has been acknowledged that tropical rainforest environments are so nutrient poor that humans could not survive 
within, without access to food crops. Recent investigations into the diets of Amazonian forest dwellers have discovered 
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that their diets consist primarily of palm nut and the seeds are ground, powdered and made into a porridge. Arils are 
also chewed and the juices are consumed. Ambiguously, these forest dwellers live very extended and healthy lives 
(Milton et al, 1991). Could it be due to the bilirubin found in the arils that forms part of their primary diet? If so, this 
could be the cytoprotective effect suspected to be the underlying characteristics of bilirubin. Sunbirds are the main 
pollinators of the white bird of paradise tree. Birds don’t produce bilirubin, they produce biliverdin. Therefore, this 
could be the reason they consume the bilirubin found in the arils. In fact, an elevated level of bilirubin, in birds after 
consumption does not impair them in anyway. Therefore, there is rationale to believe that bilirubin found in these arils 
could have a possible protective effect.  
The human body is a multifaceted being which has the aptitude to mend itself if listened to and concerned for 
correctly. However in the modern world, the variables are almost infinite. It is a fact that people of the world today are 
having more problems with their health than ever before. It is for this reason that scientists nowadays are looking at our 
pasts in order to produce medicines for the future since for hundreds of years man has used plant extracts to cure 
ailments. This study makes us believe that there is now strong experimental and theoretical support for the claim that 
bilirubin has a host of beneficial effects. 
The most important piece of evidence on the subject of bilirubin as a possible beneficial product, lies in the 
fact, that in most animal cells the degradation of haemoglobin, if stopped an action prior, with a green, soluble 
fragment called biliverdin, the desecrate would be simply emitted with no danger of detrimental accumulation. 
However, as an alternative to stopping at biliverdin, for the most part, animal cells persist on to formulate bilirubin by 
means of biliverdin reductase. If the only result of bilirubin in high amounts is toxicity, then it’s illogical that animals 
would produce it using a high energy consuming step.  
 
Conclusion 
 
In this review, the investigational as well as clinical studies on the relationships between bilirubin and its 
protective effect on certain aspects of the human body were conferred. These studies collectively illustrates that low 
serum bilirubin levels are linked with an increased risk of several pathological conditions; whereas, mildly elevated 
serum bilirubin levels provide protection. It is for this reason we can therefore hypothesize that if the bilirubin found in 
the human body has a protective effect against numerous conditions, perhaps the bilirubin found in the arils of S. 
nicolai will have similar effects and could be harnessed therapeutically to modulate certain pathological conditions. 
Clearly, detailed studies to investigate this potential further emerges necessary, and will unquestionably provide much 
needed substantiation. 
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